CARE
Carter Bankshares, Inc.
CARE's fundamentals are strong: revenue grew 77% and its operating margin rose 36 points to 63%. At 4.9x earnings, it's trading less than half its usual 12x. Its downside scenario is about eight times its upside.
CARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CARE's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CARE.
CARE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.9x | $29.10 | — |
| Cheap | 6.8x | $39.97 | +37% |
| Fair | 12x | $69.41 | +139% |
| Forward | 12x | $29.10 | — |
| Expensive | 21x | $122 | +318% |
Historical ranges are pointers, not guarantees.
CARE's PE is in its cheap range at 4.9x. Analysts expect earnings to fall, which would put today's price at 12x next year's earnings, in its fair range.
CARE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect CARE's earnings and revenue to decline, with profitability weakening.
CARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.37 | -60% |
| Q3 2026 | $5.92 | +335% |
| Q2 2026 | $5.81 | +327% |
| Q1 2026 | $4.87 | +306% |
| Q4 2025 | $1.38 | +30% |
| Q3 2025 | $1.36 | +116% |
| Q2 2025 | $1.36 | +147% |
| Q1 2025 | $1.20 | +107% |
| Q4 2024 | $1.06 | +6% |
CARE's earnings per share have climbed steadily: $5.92 over the past year, about four times what it earned the year before, and higher year over year for eight quarters in a row.
CARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $46.2M | +18% |
| Q2 2026 | $68.7M | +84% |
| Q1 2026 | $106.9M | +189% |
| Q4 2025 | $39.8M | +15% |
| Q3 2025 | $39.1M | +14% |
| Q2 2025 | $37.3M | +11% |
| Q1 2025 | $37M | +11% |
| Q4 2024 | $34.5M | +13% |
CARE's revenue has grown year over year for 10 quarters in a row: $46M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -4.5 points |
| Q2 2026 | 54% | +26 points |
| Q1 2026 | 103% | +73 points |
| Q4 2025 | 28% | -3.1 points |
| Q3 2025 | 18% | -2.2 points |
| Q2 2025 | 29% | +11 points |
| Q1 2025 | 30% | +8.4 points |
| Q4 2024 | 31% | +37 points |
CARE's operating margin was 14% last quarter, down 4.5 points from the same quarter a year ago, near the bottom of its range since 2021.
CARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5K | -100% |
| Q2 2026 | -$262.9M | -3522% |
| Q1 2026 | $302.4M | +6131% |
| Q4 2025 | $9M | +8.2% |
| Q3 2025 | $10.3M | +22% |
| Q2 2025 | $7.7M | +$12M |
| Q1 2025 | $4.9M | -70% |
| Q4 2024 | $8.3M | +37% |
CARE's free cash flow was $48M over the past year, up 56% from the year before. Free cash flow isn't a meaningful measure for financial services companies like CARE.
CARE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.6x | Net Cash |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
CARE has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CARE.
CARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 7.8 | Oversold |
CARE's weekly RSI is 48 (neutral) and its Stochastic is 8 (oversold).
CARE PE vs Financial Services Sector
| Metric | CARE | Sector median | Relative |
|---|---|---|---|
| PE | 4.9x | 13x | 62% below |
| PE % | 0 | 63 | 63 pts below |
CARE is trading at 4.9x earnings, a 62% discount to the Financial Services sector's median of 13x.
CARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.9 | 2.5% below |
| 20 week MA | $31.4 | 7.4% below |
| 50 week MA | $26.6 | 9.3% above |
| 100 week MA | $22.0 | 32% above |
| 200 week MA | $18.4 | 59% above |
CARE has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 59% above its 200-week average.
CARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.3 | $10.8 | -54% |
| 2021 | $10.8 | $14.9 | +39% |
| 2022 | $14.9 | $16.7 | +12% |
| 2023 | $16.7 | $15.0 | -11% |
| 2024 | $15.0 | $17.6 | +18% |
| 2025 | $17.6 | $19.9 | +13% |
| 2026 YTD | $19.9 | $29.1 | +46% |
CARE has finished higher in four of the last six years. It's up 46% so far in 2026.